Company & Sponsor Intelligence
Eisai Co., Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting0
Completed6
Countries1
Therapeutic footprint
alzheimersepilepsy
Indexed studies
NCT02427607An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
epilepsy · JapanPHASE3
epilepsy · JapanPHASE3
NCT03059381Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
epilepsy · JapanCOMPLETED
epilepsy · JapanCOMPLETED
NCT01539031Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
alzheimers · JapanPHASE3
alzheimers · JapanPHASE3
NCT02094729A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
alzheimers · JapanPHASE1
alzheimers · JapanPHASE1
NCT02162251Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
alzheimers · JapanCOMPLETED
alzheimers · JapanCOMPLETED
NCT00903786A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
epilepsy · JapanPHASE2
epilepsy · JapanPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →